Compare OPAL & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | ASMB |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.3M | 553.6M |
| IPO Year | N/A | 2010 |
| Metric | OPAL | ASMB |
|---|---|---|
| Price | $2.70 | $33.80 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $2.81 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 256.2K | 139.2K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $329,243,000.00 | $37,191,000.00 |
| Revenue This Year | $17.15 | $33.33 |
| Revenue Next Year | $22.04 | N/A |
| P/E Ratio | $110.95 | ★ N/A |
| Revenue Growth | 7.26 | ★ 31.30 |
| 52 Week Low | $1.26 | $7.75 |
| 52 Week High | $4.08 | $39.71 |
| Indicator | OPAL | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 59.44 | 48.81 |
| Support Level | $2.00 | $31.51 |
| Resistance Level | $2.74 | $38.99 |
| Average True Range (ATR) | 0.19 | 2.15 |
| MACD | 0.01 | -0.32 |
| Stochastic Oscillator | 89.80 | 33.29 |
OPAL Fuels Inc is a fully integrated, nationwide leader in the production and distribution of low-carbon intensity renewable natural gas. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-de-carbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.